Can we Reduce the Number of Vaccine Injections for Children?

Invasive Meningococcal Disease Clinical Trial

— MALTA  

Official title:

An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01129518
• Other study ID #: 2008_06
• Status: Completed
• Phase: Phase 4
• First received: May 21, 2010
• Last updated: November 6, 2015
• Start date: June 2010

Study information

• Verified date: November 2015
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This open label randomised controlled study will evaluate the induction of immunity following varying schedules of vaccination with glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccines in infancy. 498 infants will be enrolled in this multi-centre trial. Participants will receive either 0, 1, or 2 priming doses of a MenC-CRM197 conjugate vaccine or 1 priming dose of a MenC-TT conjugate vaccine in the first year of life, with all groups receiving a dose of a combination Hib-MenC-TT vaccine at 12 months, as well as all other concurrent routine vaccinations. All groups will also be further divided into 2 groups to receive their routine vaccines in either consistent or alternating limbs to assess the immune response to the concurrent infant routine immunisations administered in consistent versus alternating limbs. Immune responses will be assessed at 5, 12, 12months +6 days, 13 and 24 months of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 404
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 2 Months to 3 Months

Eligibility

Inclusion Criteria:

• Healthy male or female infants aged 6-12 weeks at the time of the first vaccination and who were born between 37 and 42 weeks of gestation

• Infants who are known to be free from medical problems as determined by a medical history and clinical examination

• Parents or guardians who are willing for their child to participate and who would be expected to comply with the requirements of the protocol

• Parents/guardians who have given informed consent for their child's participation in the study

Exclusion Criteria:

• History of invasive meningococcal C disease

• Previous vaccination against meningococcal serogroup C disease

• Planned administration/administration of vaccines, since birth, other than the study vaccines (with the exception of oral rotavirus vaccine, Hepatitis B vaccine and BCG).

• Receipt of investigational vaccines/drugs, other than the vaccines used in the study, within 30 days prior to receiving the first dose of the vaccines or their planned use during the study period

• Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.

• A family history of congenital or hereditary immunodeficiency.

• Receipt of more than 2 weeks of immunosuppressants or immune modifying drugs, (e.g. prednisolone >0.5mg/kg/day)

• History of allergy to any component of the vaccines.

• Major congenital defects or serious chronic illness.

• History of any neurologic disorders or seizures

• Acute disease at the time of recruitment as defined by the presence of a moderate or severe illness with or without fever (with the exception of minor illnesses such as diarrhoea, mild upper respiratory infection without fever). In such situations enrolment should be postponed until the participant has recovered.

• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period

• Parents who plan to move out of the geographical area where the study would be conducted.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Invasive Meningococcal Disease
• Meningococcal Infections

Intervention

Biological:
• Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine
In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly. Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two.
• Routine schedule immunisations except monovalent MenC vaccine
Routine schedule immunisations will be given according to NHS guidelines.

Locations

Country	Name	City	State
United Kingdom	Oxford Vaccine Group	Oxford

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	GlaxoSmithKline, Oxford University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean titres (GMTs) of meningococcal serogroup C (MenC) specific serum bactericidal antibodies, using rabbit complement (rSBA)	To demonstrate non-inferiority of the geometric mean titres (GMTs) of meningococcal serogroup C (MenC) specific serum bactericidal antibodies, using rabbit complement (rSBA), 1 month after a 12 month dose of Hib-MenC vaccine in children receiving a single dose of MenC-CRM197vaccine at 3 months of age (single dose priming) compared with those receiving 2 doses at 3 and 4 months of age (2 dose priming).	1 month after a 12 month dose of Hib-MenC vaccine	No